Cure Alzheimer's Fund Cure Alzheimer's Fund

Since our inception in 2004, our steadfast focus has been providing research grants to the worlds’ leading scientists researching Alzheimer’s disease. We are honored to work with scientists who are passionate in their pursuit to rid our world of this debilitating disease.

Many of the funded projects have resulted in significant breakthroughs in developing a better understanding of Alzheimer’s disease and getting closer to a cure.


Search

Title Researchers Date
Unlocking TREM2 Biology to Enable New Therapeutic Strategies for Alzheimer’s Disease Ana Griciuc 2026-09-29
Target Senescence Mechanisms to Restore Brain Lymphatic Drainage in Preclinical Models of Alzheimer’s Disease Sandro Da Mesquita 2026-09-29
Breaking Silos: A Bidirectional Human Framework Linking Vascular Dysfunction and Tauopathy Across Dementias Fanny Elahi 2026-09-29
Enhancing Anti-Amyloid Therapeutic Efficacy Through SHIP1-Mediated Modulation of Microglial Function in Alzheimer’s Disease Adrian Oblak 2026-09-29
Defining the Presynaptic Molecular Switch Linking Amyloid Pathology to Tau Pathogenesis Jeffrey Savas 2026-09-29
Rejuvenating Amyloid-Induced Dysfunction in the Oligodendrocyte–Microglial Niche via Youth-Associated Blood-Borne Factors Joseph Castellano 2026-09-29
Defining and Targeting Mechanisms of APOE4 Cerebrovascular Dysfunction and Amyloid Accumulation in Alzheimer’s Disease Joel Blanchard 2026-09-29
Targeting the Microglial Checkpoint LILRB4 to Enhance Protective Amyloid Clearance in Alzheimer’s Disease Marco Colonna 2026-08-17
Cell Type-Specific Interpretation of Alzheimer’s-Associated Genetic Variants Andreas R. Pfenning 2026-08-13
Deep Mass Spectrometry Profiling of Tau Aggregates in Alzheimer’s Disease and Other Tauopathies Henrik Zetterberg Gunnar Brinkmalm 2026-08-13
Identifying Functional Variants in Alzheimer’s Disease Mark Ebbert 2026-08-13
Dissecting How Amyloid Beta Triggers Tau Pathology in Late-Onset Alzheimer’s Disease Using Patient-Derived Neurons Zhao Sun 2026-08-10
Advancing Risk Prediction for Alzheimer’s Disease Using Integrated Blood, Neuroimaging, and Clinical Biomarkers Rachel Buckley 2026-08-03
Assessment of the Antimicrobial Peptide Activity of Amyloid Beta Under Physiological Conditions in APP Knock-In Mice Deepak Kumar Vijaya Kumar 2026-07-27
Unraveling Female Vulnerability: Sex Hormones, Diabetes Status and Modifiable Risk in Alzheimer’s Disease Erin Sundermann Sarah Banks 2026-07-16
Gut-Mediated Mechanisms of APOE4 in Alzheimer’s Disease: Toward New Therapeutic Targets Barbara B. Bendlin 2026-07-16
The Jeffrey L. Morby Prize (Disentangling Age- and Alzheimer’s Disease-Related Effects on CSF MTBR-Tau Species) Randall J. Bateman Oskar Hansson 2026-07-14
Neuroimmune Consortium: Neuroimmune Mechanisms Linking Peripheral Infection-Induced Dysregulation of Perivascular Amyloid Beta Clearance and Amyloid Pathology Beth Stevens 2026-06-03
Neuroimmune Consortium: Astrocyte Inflammatory Contributions to Alzheimer’s Disease Shane Liddelow 2026-06-03
Neuroimmune Consortium: Understanding Responses of the Brain to Peripheral Sources of Inflammation Christopher K. Glass 2026-06-03